Last updated: July 16, 2026
What is the Pierre Fabre Dermatologie v. Annora Pharma Private Limited case (1:22-cv-01442) about?
Executive summary: 1:22-cv-01442 is a U.S. patent infringement suit filed by Pierre Fabre Dermatologie against Annora Pharma Private Limited. The record needed to produce a complete litigation summary (asserted patents, accused products, procedural posture, and case-dispositive events) is not present in the information provided.
Because the prompt does not include the complaint’s asserted patent numbers, the drug/product in dispute, the FDA reference product or Orange Book context, or any docket outcomes, a complete and accurate litigation analysis cannot be generated.
Which patents does Pierre Fabre Dermatologie assert in 1:22-cv-01442?
A litigation summary requires the specific asserted patent list (publication numbers and/or U.S. patent numbers), including:
- patent family identifiers
- claims asserted (independent claim set and representative dependent claims)
- any allegation of inducing/contributing infringement
- ownership/assignment chain for each asserted patent
No such patent-identifying data is included.
What products are accused in Pierre Fabre Dermatologie v. Annora Pharma (1:22-cv-01442)?
A defensible analysis requires:
- the exact Annora product name(s) or ANDA/505(b)(2) submission identifier(s)
- strength, dosage form, and formulation characterization
- whether the case alleges method-of-use infringement versus composition/formulation infringement
- whether any biosimilar-style comparisons apply (unlikely in a typical dermatology small molecule case, but the product class must be verified)
No accused-product identifiers are provided.
What is the procedural posture and timeline for 1:22-cv-01442?
A litigation timeline needs docket dates for:
- filing of complaint
- service and answer deadlines
- motions to dismiss and claim construction schedules
- Markman date(s)
- preliminary injunction request and ruling dates (if any)
- summary judgment filings
- trial dates or case-dispositive settlement events
- final judgment entries
No docket timeline data is included.
What motions or defenses did Annora Pharma raise in 1:22-cv-01442?
A credible analysis requires the pleaded defenses, such as:
- invalidity grounds (35 U.S.C. §§ 101, 102, 103, 112)
- unenforceability (inequitable conduct, prosecution history estoppel)
- non-infringement claim chart positions
- venue/personal jurisdiction challenges
- Noerr-Pennington or statute-of-limitations issues (case-specific)
- limitation of asserted claims
No defense content is provided.
How do court rulings affect claim scope in 1:22-cv-01442?
Litigation strength and value depend on claim construction and evidentiary rulings. A proper analysis requires:
- the court’s Markman orders (terms construed, reasoning, and outcomes)
- any Daubert rulings on expert testimony
- rulings on preliminary injunction standards and irreparable harm findings
No rulings are provided.
Was there a Paragraph IV filing and what does it imply for exclusivity exposure?
Patent litigation in the Hatch-Waxman context typically follows an Abbreviated New Drug Application (ANDA) with certifications (Paragraph I-IV, or related 505(b)(2) structures). A summary requires:
- FDA application number
- certification type per asserted patent
- date of FDA notice of certification
- whether a 30-month stay was triggered and when it ends
- any settlement timing that impacts launch risk
No FDA certification data is included.
What is the Orange Book and FDA regulatory status for the relevant Pierre Fabre product?
To connect the litigation to launch timing, an analysis must map:
- listed Orange Book patents for the listed NDA/Reference Product
- expiry dates (patent term and any patent restoration)
- exclusivity: NCE, 505(b)(2) exclusivity, 3-year exclusivity, pediatric exclusivity
- whether Annora is seeking a generic or a 505(b)(2) pathway
No Orange Book or FDA details are included.
Which other competitors or challengers are implicated alongside Annora?
A high-value litigation landscape analysis requires identification of:
- co-defendants in parallel cases
- other ANDA filers for the same reference product/patents
- any coordinated settlements or consortia behavior
No competitor-identification data is provided.
How strong is Pierre Fabre’s patent estate in this litigation context?
Patent estate strength analysis depends on:
- claim survivability based on prosecution history and prior art landscapes
- whether asserted patents are core compound/formulation versus narrower device/process claims
- family breadth by jurisdictions (US only is insufficient for commercial and settlement dynamics)
- whether there are multiple independent claim sets covering the accused design
No asserted-patent identities are included, so strength cannot be computed.
What settlement or licensing outcomes are available for 1:22-cv-01442?
Settlement impact requires:
- any court-entered consent judgment
- settlement agreement terms (design-around timelines, licensor royalty, covenants not to sue)
- any non-monetary terms affecting manufacturing or launch
No settlement information is provided.
What generic entry risks exist for Annora’s launch under a worst-case scenario?
Launch-risk assessment needs:
- what patents are still asserted at the time of any dismissal or settlement
- whether any remaining patents would block regulatory approval or market entry
- whether design-around is feasible without triggering doctrine of equivalents
- whether FDA approval triggers automatic launch or is contractually stayed
No procedural endpoint or patent list is included.
Key Takeaways
No litigation summary or infringement/validity/strategy analysis can be produced from the information provided. The required facts for 1:22-cv-01442, including asserted patents, accused products, docket posture, and any dispositive rulings, are not present.
FAQs
- What information from the complaint is required to map asserted patents to Orange Book listings?
- How do Markman claim construction outcomes typically shift infringement versus invalidity leverage?
- What docket events signal a probable settlement or covenant-not-to-sue rather than trial?
- How does a 30-month Hatch-Waxman stay affect FDA launch timing after dismissal?
- What evidence is usually most probative for formulation or dermatology product infringement disputes?
References
- (No sources provided in the prompt.)
